The 19th Annual
Peptide Therapeutics

October 22-23, 2024
Scripps Seaside Forum

Registration Opens In July
2024 Symposium Sponsors

Past Symposia

18th Annual Peptide Therapeutics Symposium, October 2023

The Structure-function of the Endocrine FGFs: Nature Repeats Itself
Archita Agrawal, Ph.D.

One Ellipsoid to Rule Them All — Cathelicidin-mimicking Peptoids that are Antiviral, Antibacterial & Antifungal and Well-tolerated in the Airways
Annelise Barron, Ph.D.

Harnessing the Power of Molecular Imaging for Precision Medicine: Radiolabeled Peptides, Antibodies, and Everything in Between
Weibo Cai, Ph.D.

Activation of the Insulin Receptor by Insulin and Non-insulin Peptide: Application in Human Disease
Eunhee Choi, Ph.D.

Peptide Therapeutics for the Treatment of Obesity and Type 2 Diabetes
Ruth Gimeno, Ph.D.

Radionuclide Theranostics: Current State and Future Perspectives
Ken Herrmann, MD, MBA

Pegcetacoplan: The CMC Journey through Development to FDA Approval
Chris Holmes, Ph.D.

Advances in Oligonucleotide Delivery to Muscle Using Antibody Oligonucleotide Conjugates (AOCs): Transferrin Receptor 1 (TfR1) Mediated Uptake of AOCs for the Treatment of Muscular Dystrophies
Arthur A. Levin, Ph.D.

Safe and Effective Delivery of Nucleic Acids Using Proteolipid Vehicles Formulated with Fusion-Associated Small Transmembrane Proteins
John Lewis, Ph.D.

Neuregulin 4 (NRG4) as a New Hormonal Therapy for NASH-related Liver Cancer
Jiandie Lin, Ph.D.

Establishing a Novel Platform for Discovery of CPPs that Localize in Cytoplasm
Jinsha Liu, Ph.D.

Amylin: State of the Union
Tom Lutz, Ph.D.

The Interplay of Insulin and Glucagon: From Physiology to Pharmacology
David Maggs, MD, FRCP

Computational Design of Novel Peptides for SORT1 and Their Use in Oncology
Lucas Siow

Stealth Editing™ – A Novel Non-Immunogenic In Vivo Gene Editing Technology
Dietrich Stephan, Ph.D.

Development of Efruxifermin, an FGF21 Analog, for Treatment of Nonalcoholic Steatohepatitis (NASH)
Jonathan Young, Ph.D., J.D.

17th Annual Peptide Therapeutics Symposium, October 2022

Conjugate for the Treatment of Obesity
Yuan Cheng, Ph.D.

Exploration of Improved MC4R Agonist and Novel MC3R Antagonist Peptides for the Treatment of Obesity
Roger Cone, Ph.D.

A Hundred Years Ago Today the Band Began to Play
Richard DiMarchi, Ph.D.

From Serendipity to Rational Design: Multimodality Therapeutics for Multimorbidity Diseases
Brian Finan, Ph.D.

Development of Differentiated Peptide Therapeutic Products Using an Innovative Formulation Technology
Jan Jezek, Ph.D.

Chemical Optimization of the Pancreatic Glycemic Hormones
John P. Mayer, Ph.D.

GLP1 Receptor Bias Agonists: The Long and Short of It
Patricia McDonald, Ph.D.

Ionic Liquids for Delivery of Biologics
Samir Mitragotri, Ph.D.

Oral Inhibitors of the SARS-CoV-2 Main Protease for the Treatment of COVID-19
Dafydd Owen, Ph.D.

Engineering Long-acting Relaxin ThP – AZD3427
Monika Papworth, Ph.D.

Discovery and Characterization of Novel Peptides and Small Proteins
Alan Saghatelian, Ph.D.

CryoEM After the Resolution Revolution: Achievements, Developments and Challenges
Annette Schneemann, Ph.D.

The Next Generation of RaPID System
Hiroaki Suga, Ph.D.

A New Approach to Cancer Therapy with Documented Clinical Effects
Catharina Svanborg, M.D., Ph.D

Invention of Oral PCSK9 Inhibitor from mRNA Display Selection
Abbas M. Walji, Ph.D.

16th Annual Peptide Therapeutics Symposium, October 2021

Design and Evaluation of Synthetic Lipopeptides as Potent Antivirals
Christopher A. Alabi, Ph.D.

Development of Next Generation Incretin Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist Peptide
Jordi Alsina, Ph.D.

The Coming of Age of De Novo Protein Design
David Baker, Ph.D.

G Protein-Coupled Receptors: From Structure to Cell Specific Drug Targeting
Annette Beck-Sickinger, Ph.D.

RNA Therapeutics: New Chemical Modalities Becoming a Therapeutic Reality
Konrad Bleicher, Ph.D.

Applications of Covalent Peptide Probes for Imaging of Cancer and Infectious Diseases
Matthew Bogyo, Ph.D.

Peptide-Based Therapeutics: Paving the Way from the Lab to the Clinic
Dame Margaret Brimble DNZM, FRS, Ph.D.

Use of Integrin Antagonists to Disrupt Pathological Mechanical Force-Dependent Processes in Fibrosis and Severe Asthma
William DeGrado, Ph.D.

GLP-1 Action-Mechanisms and Future Directions
Daniel Drucker, Ph.D.

The Use of GLP-1 Receptor Agonists for the Treatment of Parkinson’s Disease
Tom Foltynie, Ph.D.

Toward Novel Therapeutics via Directed Remodeling of the Gut Microbiome
M. Reza Ghadiri, Ph.D.

Dasiglucagon, a Next-generation Ready-to-use Glucagon Analog and its Potential Use in Bi-Hormonal Artificial Pancreas Pumps
Rie Schultz Hansen, MSc, Ph.D.

Defining the Melanocortin GPCR System for Non-Opioid Analgesia and Peripheral Diabetic Neuropathic Pain Therapeutic Development
Carrie Haskell-Luevano, Ph.D.

Identification, Characterization and Development of Dual Amylin and Calcitonin Receptor Agonists as Novel Drug Candidates Providing Insulin Sensitization and Weight Loss
Kim Henriksen, Ph.D.

PYY Analogs for the Treatment of Obesity and Type 2 Diabetes
Anish Konkar, Ph.D.

Personal Peptide Vaccines Directed at Neoantigens for Patients with Advanced Solid Tumors
Patrick A. Ott, MD, Ph.D.

Recifin A, a Novel and Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase I with a Unique Disulfide-bond Topology
Christina I. Schroeder, Ph.D.

15th Annual Peptide Therapeutics Symposium, October 2020

Vasopressin: Old Dog. New Tricks.
Michael J. Brownstein M.D., Ph.D. | Senior Vice President, Drug Development
Azevan Pharmaceuticals

Adrenomedullin Functions at the Maternal-Fetal Interface
Kathleen Caron, Ph.D. | Professor & Chair, Department of Cell Biology and Physiology
University of North Carolina at Chapel Hill

GEN-009: A Neoantigen Vaccine Based on Autologous Peptide Immune Responses
GEN-011: Transforming T Cell Therapy for Solid Tumors
Daniel B. DeOliveira, Ph.D., PMP | Senior Director; Peptide Dev., Tech. Ops. & Mfg.
Genocea Biosciences Inc.

Peptides for Molecular Recognition and Brain Delivery
Ernest Giralt, Ph.D. | Professor
Institute for Research in Biomedicine (IRB Barcelona)

Novel Pairings in the Human Peptide-Receptor Signaling System
David Gloriam, Ph.D. | Professor
University of Copenhagen

Deadly Cures: A Spider-Venom Peptide for Treating Ischemic Injuries of the Heart and Brain
Glenn King, Ph.D. | Institute for Molecular Bioscience
The University of Queensland, Australia

Building Novel Immune Cell Agonist Anti-Cancer Agents out of Bicycle Parts
Kevin McDonnell, Ph.D. | Vice President, Chemistry
Bicycle Therapeutics

Chimeric Macrocyclic Peptide Antibiotics Against WHO Priority 1 Gram-Negative Bacteria Targeting both Lipopolysaccharide and BamA
Daniel Obrecht, Ph.D. | CSO
Polyphor Ltd

Cyclic Cell-Penetrating Peptides: Mechanism of Action and Applications
Dehua Pei, Ph.D. | Kimberly Professor of Chemistry and Biochemistry
The Ohio State University

Empowering Peptide Science through Easy 18F-Labeling for PET Imaging and New Stapling Methods Inspired by Natural Product Toxins
David M. Perrin, Ph.D. | Professor, Chemistry Department
University of British Columbia

Novel Therapeutics for Inflammatory Disorders of Pregnancy – Opportunities and Challenges
Sarah Robertson, Ph.D., FAA, FAHMS | Professor and Director
Robinson Research Institute, The University of Adelaide

A Peptide Engineering Platform for PEG-FA Stapled Long-Acting Peptide Hormones
Weijun Shen, Ph.D. | Director, Metabolic Disease
Calibr at Scripps Research

GI Device Development in a Few Movements
Giovanni Traverso, MB, BChir, Ph.D. | Assistant Professor, Department of Mechanical Engineering, Massachusetts Institute of Technology, Assistant Professor of Medicine (part-time), Division of Gastroenterology, Brigham and Women’s Hospital, Harvard Medical School

Toward Universal Druggability
Greg Verdine, Ph.D. | Erving Professor of Chemistry, Harvard University and Harvard Medical School; President and Chief Executive Officer, Fog Pharmaceuticals and LifeMine Therapeutics

From Farm to Pharmacy: A Strawberry-Derived Solution to Oral Protein Delivery
Kathryn Whitehead, Ph.D. | Associate Professor
Carnegie Mellon University

Dual Myristic Acid (Myr) and Trans Activator of Transcription (Tat) Conjugated Peptides: A Potential Platform Technology for Intracellular Cargo Delivery
Lindon H. Young, Ph.D. | Professor of Pharmacology, Philadelphia College of Osteopathic Medicine; Founder & Chief Science Officer, Young Therapeutics
Kerry-Anne A. Perkins D.O | Obstetrician & Gynecologist
Virtua Memorial Hospital

14th Annual Peptide Therapeutics Symposium, October 2019


Discovery and Characterization of Viral Insulin-like Peptides
Emrah Altindis, Ph.D. | Assistant Professor
Biology Department, Boston College

Elastin-Like Polypeptide Biopolymers Enhance the Pharmacology of Therapeutic Peptides
Jim Ballance, Ph.D. | VP Research & Scientific Affairs
PhaseBio Pharmaceuticals, Inc.

Molecular Mechanisms of Transcriptional Control by Intrinsically Disordered Proteins (aka Peptides)
Rebecca B. Berlow, Ph.D. | Staff Scientist
Department of Integrative Structural and Computational Biology
Scripps Research &
H. Jane Dyson, Ph.D. | Professor
Department of Integrative Structural and Computational Biology
Scripps Research

Redesign of Vancomycin for Resistant Bacteria
Dale L. Boger, Ph.D. | Richard and Alice Cramer Professor of Chemistry
Department of Chemistry, Scripps Research

Oral Delivery of Peptides: Present and Future
Stephen T. Buckley, Ph.D. | Head of Discovery ADME
Novo Nordisk A/S

Targeting Intracellular Pathogenic Bacteria with Unnatural Proline-Rich Peptides
Jean Chmielewski, Ph.D. | AW Kramer Distinguished Professor
Department of Chemistry, Purdue University

Mini-Ins: A Minimized, Bioactive Insulin Analog with Fast-Acting Properties Inspired by A Cone Snail
Danny Chou, Ph.D. | Assistant Professor of Biochemistry
University of Utah, School of Medicine, Department of Biochemistry

Peptide Science 1968-2019, A Retrospective
Victor J. Hruby, Ph.D. | Regents Professor
Department of Chemistry and Biochemistry, University of Arizona

GLP-1@Novo Nordisk: Innovating with Fatty Acid Acylation
Lotte Bjerre Knudsen, DMSc | Professor, Scientific Corporate Vice President
Novo Nordisk A/S, Global Drug Discovery

Evidence of Central Signaling after Administration of Oxytocin at Olfactory and Peripheral Sites
Mary R. Lee, M.D. | Associate Research Physician
Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology
National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse Intramural Research Programs

GAP Chemistry and Multi-Layer 3D Chirality for the Synthesis of Amines, Amino Acids and Peptides
Guigen Li, Ph.D. | Paul Whitfield Horn Professor
Department of Chemistry & Biochemistry

Development of Bifunctional Mu Opioid Receptor (MOR) Agonists/ Delta Opioid
Receptor (DOR) Antagonists: Opioid Analgesics with Improved Side Effect Profiles
Henry I. Mosberg, Ph.D. | Tom D. Rowe Professor of Medicinal Chemistry
College of Pharmacy, University of Michigan

A Dual ApoC-II Mimetic-apoC-III Antagonist Peptide for Lowering Plasma Triglycerides
Alan T. Remaley, M.D., Ph.D. | Senior Investigator
NHLBI, National Institutes of Health

Peptide Drug Hunter: Innovation, Integration and Inspiration
Tomi K. Sawyer, Ph.D. | Entrepreneurial Drug Hunter
Maestro Therapeutics

Potent Antibody-Based Conjugates for Cancer Therapy: From Early Stage Research to a Clinically
Approved Drug
Peter Senter, Ph.D. | Vice President for Chemistry and Distinguished Research Fellow
Seattle Genetics

Discovery of FE 201836, a Short Acting V2R Agonist for the Treatment of Nocturia
Kazimierz Wisniewski, Ph.D. | Senior Scientist II
Ferring Research Institute, Inc.

Structural Basis of Signal Recognition and Regulation at the Full-length Glucagon Receptor
Beili Wu, Ph.D. | Professor
Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Poster Abstracts

P01 High Throughput Discovery of Novel Peptides with Biological Function
Francesca Billwiller, Giulia Poloni, Bethany Marshall, Xiaoyan Pan, Xiaoju Ni, Anthony Pitt
ORBIT Discovery, Heatley Rd, Oxford, Oxfordshire OX44GE, UK

P02 High-Efficiency Solid Phase Synthesis of Peptides and Peptidomimetics with the Liberty Blue
Alexandria Brackbill, Isaiah Gober
CEM Corporation, 3100 Smith Farm Road, Matthews, NC 28104, USA

P03 Structure-based Drug Design (SBDD) and In Silico Pharmacophore Screening Approaches Combined with Biochemical Validation Enabled the Discovery of Di- and Tetrapeptides Inhibitors of Y-49 and ampC Beta Lactamases
Cristina Clement1,2 Janet Gonzalez3, Sheuli Zakia4, Sangeeta Tiwari5, Manfred Philipp1
1Chemistry Department, Lehman College of CUNY, Bronx, New York, 1048, USA; present address: 2Radiation/Oncology, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065, USA; 3Natural Sciences, LaGuardia Community College, Long Island City, New York, USA; 4Laredo Community College, Laredo, Texas, USA; 5Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

P04 The Effects of Novel Myristic Acid Conjugated Protein Kinase C Beta II Activator and Inhibitor Peptides on Phorbol 12-myristate 13-acetate-induced Superoxide Release in Isolated Rat Polymorphonuclear Leukocytes
Tameka Dean, Annam Humayun, Jennifer Dang, Daphne Metellus, Arjun Nair, Faosat Muftau-Lediju, Rose Martorana, Anahi McIntyre, Qian Chen, Robert Barsotti, Lindon Young Philadelphia College of Osteopathic Medicine (PCOM), 4170 City Ave, Philadelphia, PA 19131, USA

P05 The Effects of Novel Myristoylated PKC Epsilon Peptide Activator and Inhibitor on Nitric Oxide Release in Cultured Human Umbilical Vein Endothelial Cells
Tameka Dean, Chantel Thompson, Claudine Andre, Gordon Heller, Ahsal Major, Rose Martorana, Ian Madison, Jeremy Castro, Qian Chen, Robert Barsotti,
Lindon Young Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, 4170 City Avenue, Philadelphia, PA 19131, USA

P06 Spontaneously Cleavable Glycosylated Linkers for Peptides without Suitable Glycosylation Sites
Hirofumi Ochiai, Sofia Elouali, Akio Kanatani, Yuji Nishiuchi
GlyTech, Inc., KRP #1-109, 134 Chudojiminami-machi, Shimogyo-ku, Kyoto, 600-8813, Japan

P07 Overcoming the Blood-brain-barrier by a Linear 7-mer Peptide, IF7, with Binding Specificity to Annexin A1 in Brain Tumors
Michiko N. Fukuda
Cancer Center, Sanford-Burnham-Prebys Medical Discovery Institute, 10901 North Torrey Pines Rd., La Jolla, CA 92037, USA

P08 Illuminating the Assembly and Cellular Interactions of a Trimer Derived from Aβ
Gretchen Guaglianone, Stan Yoo, Adam G. Kreutzer, James S. Nowick
Department of Chemistry, University of California, Irvine, California 92697-2025, USA

P09 Chimeric Interleukin-15 Bovine Ultralong Antibody Fusion for Potential Cancer Therapy
Ruiqi Huang, Vaughn Smider
Applied Biomedical Science Institute, 10929 Technology Pl, San Diego, CA 92127, USA

P10 Suppression of Hypermetabolic Response with a Peptide Targeting a Brown Fat Vascular Marker
Mikhail Kolonin, Alexes Daquinag, Zhanguo Gao
UT Health, 1825 Pressler St., Houston, TX 77030, USA

P11 An Improved Ornithine Turn-Linker for the Stabilization of a Peptide Derived from Aβ17-36
Xingyue Li, Patrick Salveson, Andrew Sabol, Adam Kreutzer, James S. Nowick
Department of Chemistry, University of California-Irvine, 8511 Palo Verde Rd, Irvine, California 92697-2025, USA

P12 Myristoylated Protein Kinase C Beta II Peptide Inhibitor Exhibits Robust Attenuation of Myocardial Ischemia/Reperfusion Injury in Rats
Ian T. Madison, Melinda A. Beale, Daphne Metellus, Jeremy Castro, Michael F. Lloyd, Redona Gjoka, Rose M Martorana, Anahi McIntyre, Qian Chen, Robert Barsotti, Lindon Young
Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, 4170 City Avenue, Philadelphia, PA 19131, USA

P13 Amphiphilic Tricyclic Peptides: Design, Synthesis, and Biological Evaluation of as Molecular Transporters
Sumit Kumar, Rakesh Tiwari, Keykavous Parang
Chapman University, 9401 Jeronimo Road, Irvine, CA 92618, USA

P14 Searching for Faster and Efficient Solid Phase Peptide Synthesis Methods for Increased Crude Purity in Reduced Time
Cyf N. Ramos-Colón, Daniel Martinez, Andrew Kennedy, James Cain
Gyros Protein Technologies, 4675 S. Coach Dr., Tucson AZ, USA

P15 Effects of N-terminal Extensions on the Assembly of Macrocyclic β-sheet Peptides Derived from Aβ(16-36)
Tuan Samdin, Michał Wierzbicki, Adam Kreutzer, William Howitz, Mike Valenzuela, Alberto Smith, Victoria Sahrai, Nicholas Truex, Matthew Klun, James S. Nowick
Department of Chemistry, University of California, Irvine, California 92697-2025, USA

P16 AutoDock CrankPep: Docking Fully Flexible Large Peptides
Yuqi Zhang, Michel F. Sanner
Scripps Research, 10550 North Torrey Pines Rd., La Jolla, CA 92037, USA

P17 Distributed Drug Discovery (D3) Synthesis and Testing of Multiple Unnatural Dipeptides Identifies a Subset with Potent Antimicrobial Activity against Pseudomonas aeruginosa (Pa)
William L. Scott,*ª Martin J. O’Donnell,ª J. Geno Samaritoni,ª Kathy Marrs,ª Gregory G. Anderson,ª Amy B. Dounay,b Amelia A. Fuller,c Luis Miranda,d Ingrid Montes,e Guillermo Morales,f Doug Schirch,g Kevin Sullivanh
ªIndiana University Purdue University Indianapolis (IUPUI), 402 N. Blackford Street, Indianapolis, IN 46202, USA; bColorado College; cSanta Clara University; dUniversidad Nacional Autónoma de México; eUniversity of Puerto Rico, fInnoventyx; gGoshen College; hUniversity of Indianapolis

P18 Hyperdisulfide and Cell-Penetrating Cytoprotective Peptides from Medicinal Plants
James P Tam, Bamaprasad Dutta, Janet To
School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551

P19 Evaluation of Structure-Activity Relationship of Cyclic Peptides [W4R4] and Amphipathic Fatty Acyl-Cyclic [W4R4K] as Potential Antibacterial Agents Against Pathogenic Bacteria
Ajayi Akinwale¹, Jason Yamaki², Keykavous Parang¹, Rakesh K. Tiwari¹
¹Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, 9401 Jeronimo Road, Irvine, California 92618, USA; ²Department of Pharmacy Practice, Chapman University School of Pharmacy, Harry and Diane Rinker Health Science Campus, Irvine, California 92618, USA

P20 N-linked Glycosylation Increases Stability and Efficacy of Bivalirudin In Vitro
Marcus Van Engen, Jenna Veenstra, Lily Smith, Bennett Harmelink, Victoria Cast, Hailiang Joshua Zhu
Dordt University Department of Chemistry, 700 7th St NE, Sioux Center, IA 51250, USA

P21 A Dual apoC-II Mimetic-apoC-III Antagonist Peptide for Lowering Plasma Triglycerides
Anna Wolska¹, Larry Lo², Denis O. Sviridov¹, Mohsen Pourmousa³, Milton Pryor¹, Soumitra Ghosh², Rahul Kakkar², Michael Davidson², Sierra Wilson¹, Richard W. Pastor³, Jingrong Tang¹, Marcelo Amar¹, Matt Devalaraja², Alan T. Remaley¹
¹Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Build. 10, Rm. 5D15, Bethesda, MD 20892, USA; ²Corvidia Therapeutics, Waltham, MA, USA; ³Laboratory of Computational Biology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA

P22 Anti-DKK2 D-peptide Inhibitor, One Drug With Multiple Effects on Metastatic Colorectal Cancer Treatment
Weiliang Xu, Michael S. Kay
Department of Biochemistry, University of Utah School of Medicine, 15 North Medical Drive East, Room 3280, Salt Lake City, Utah 84112-5650, USA

P23 Synthesis and Characterization of a Methylene Thioacetal Human Insulin Analog with Enhanced Stability
Nan Zheng, Danny Chou
Department of Biochemistry, University of Utah, 15 N Medical Drive EEJMRB East Room 4520, Salt Lake City, UT 84112, USA

13th Annual Peptide Therapeutics Symposium, October 2018


ALRN-6924, a Stapled α-helical Peptide, Reactivates Wild-type p53 by Inhibiting MDMX and MDM2 in in vitro Cell Assays, in vivo animal Models, and in Patients with Cancer
Manuel Aivado, Ph.D., M.D.
President and Chief Executive Officer, Aileron Therapeutics, Inc.

Extending the Circulating Half-life of Clot Factors by Conjugation to the Natural Carbohydrate Polymer Heparosan
Carsten Behrens, Ph.D.
Principal Scientist, Novo Nordisk A/S

Development of Avexitide for Treatment of Post-Bariatric Hypoglycemia
Colleen M. Craig, M.D.
Director of Clinical Development, Metabolic Diseases, Eiger BioPharmaceuticals

BioChaperone®: A Platform to Improve Solubility and Stability of Therapeutic Proteins and Peptides
Stephen Daly
US General Manager, Adocia

Peptidic Therapeutics Update
Michael K. Dunn, Ph.D.
Senior Director, Scientific Information & Intelligence, Ferring Research Institute, Inc.

Chemically Synthesized Glycosylated Somatostatin Analogs with High Metabolic Stability and Native-like Binding Affinity to all Five Receptor Subtypes
Sofia Elouali, Ph.D.
Researcher, GlyTech, Inc.

Constrained Peptides and Mini Proteins as Novel Therapeutics Targeting p53
Sir David Lane, FRS
Chief Scientist of A*STAR; Director, p53Laboratory, BMSI, A*STAR

Houdini Proteins: Discovery and Applications of Ultrafast Inteins
Tom W. Muir, Ph.D.
Chair, Department of Chemistry, Princeton University

Efficient Chemo-enzymatic Synthesis (CEPS) of Incretin Peptides
Timo Nuijens, Ph.D.
CSO, EnzyPep. B.V.

Glepaglutide, a Novel Long-acting Glucagon-like Peptide-2 Analog for the Treatment of Patients with Short Bowl Syndrome
Andrew Parker, MBA, Ph.D.
Secretary and Director, Peptide Therapeutics Foundation; CSO and EVP, Head of Research and External Innovation, Zealand Pharma

Definition of Endocrine FGF Structure as a Means to Super-agonism
Sebastian Parlee, Ph.D.
Senior Scientist, Novo Nordisk Research Center, Indianapolis

Targeting Eph Receptors with Agonist and Antagonist Peptides
Elena B. Pasquale, Ph.D.
Professor, Tumor Initiation and Maintenance Program and Director of Academic Affairs, Sanford Burnham Prebys Medical Discovery Institute

Alternative Forms and Activities of Human tRNA Synthetases in Biology and Disease
Paul Schimmel, Ph.D.
Ernest and Jean Hahn Professor of Molecular Medicine and of Chemistry, The Scripps Research Institute

Injectable Peptide Gels for the Local Delivery of Drugs
Joel Schneider, Ph.D.
Deputy Director, Center for Cancer Research Chief, Chemical Biology Laboratory, National Cancer Institute, NIH

Modulating Biological Signaling Through Protein and Small Molecule Design for Therapeutic Purposes
Jim Wells, Ph.D.
Professor and Chair, Department of Pharmaceutical Chemistry, University of California, San Francisco

About the High Resolution Aβ(1-42) Fibril Structure – and the Orally Available Clinical Stage all-d-enantiometric Peptide PRI-002 that Reverts Cognition Deficits and Decelerates Neurodegeneration in Transgenic AD Mouse Models
Dieter Willbold, Ph.D.
Director, Institut für Physikalische Biologie, HeinrichHeine-Universität Düsseldorf, Düsseldorf, Germany; Director, Institute of Complex Systems, ICS-6: Structural Biochemistry, Research Centre Jülich, Jülich, Germany

Identifying and Targeting Tumor Neoantigens
Catherine J. Wu, M.D.
Professor of Medicine, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School

Poster Abstracts

Early Development of a KISS1/GPR54 Receptor Agonist for Prostate Cancer
Yvonne Angell
Department of Chemistry, ChemPartner

Design and Synthesis of Brain Penetrant Glycopeptide Analogues of Pituitary Adenylate Cyclase Activating Peptide (PACAP) for the Treatment of Parkinson’s Disease
Christopher R. Apostol
Department of Chemistry & Biochemistry, The University of Arizona, Tucson

A Nanoformulation Of Lipase With Cellulose Embodied Polypyrrole Functionalized Graphene Oxide Nanocomposite As Promising Nanobiocatalyst: Characterization, Stability Insights And Application
Mohd Shamoon Asmat
Department of Biochemistry, Faculty of Life Sciences Aligarh Muslim University

Synthesis of a Competitive Stapled Peptide Inhibitor for CHP-NHE1 Protein-Protein
Bell, I
University of San Diego, CA

Efficient Cytosolic Delivery of Molecular Cargo Mediated by Lipid-specific Endosomal Escape of Supercharged Branched Peptides
Dakota J. Brock
Department of Biochemistry and Biophysics, Texas A&M University

Insulin Macrocyclization Explores the Relationship Between Conformation and Biological Activity
Brunel, FM
Novo Nordisk Research Center

Identification of Microprotein-Protein Interactions via APEX Tagging
Qian Chu
Salk Institute for Biological Studies

Antibacterial and Non-cytotoxic Peptide Ferived from the p- BthTX-I
Eduardo M. Cilli
Institute of Chemistry, São Paulo State University

Structure-based Design, Synthesis and Evaluation of D-3,3-Diphenylalanine-based Tetrapeptides Inhibitors of Thrombin-activated Platelets Aggregation and Potent Anticoagulants
Cristina Clement
Albert Einstein College of Medicine

Strategies Toward Optimizing Automated On-resin Disulfide Bond Formation in Disulfide Rich Peptides
Elizabeth Denton

Leveraging the Knorr Pyrazole Synthesis for the Facile Generation of Thioester Surrogates for use in Native Chemical Ligation
Dillon T. Flood
The Scripps Research Institute

Sequence Alignments and Peptide Optimization
Mark R. Hansen

Discovery of a potential target for the development of therapeutic peptides for preventing bacterial- mediated colorectal cancer
Anthony Harrington
Department of Chemistry, University of Nevada

Chemical Syntheses of Teixobactin and Structural Analogs
Antoine Henninot
Ferring Research Institute

Development of a Multi-step Purification of Liraglutide
Marc Jacob

Dissolution of β-sheet Stacking of Peptide Fibrils by Using Intense Mid-infrared Laser
Takayasu Kawasaki
IR Free Electron Laser Research Center

Cost Effective Peptide Purification via ZEOsphere DRP Mixed-Mode Chromatography
Jürgen Machielse
Zeochem AG

Annotation of Protein-Coding Small Open Reading Frames in the Human Genome
Thomas Martinez
Salk Institute for Biological Studies

Rationally Designing the Most Potent Agonists and Antagonists for the Enterococcus faecalis fsr Circuit: Improving Attenuation of Quorum Sensing-Dependent Pathogenicity
Dominic McBrayer
University of Nevada, Las Vegas

BioChaperone Technology Enables the Development of Pramlintide-prandial Insulin Combinations
G. Meiffren

Protein Kinase C Beta Peptide Activator and Inhibitor Regulation of Phorbol 12- myristate 13-acetate (PMA) and N-formyl-L-methionyl-L-leucyl-L- phenylalanine (fMLP) Induced Superoxide Release in Polymorphonuclear Leukocytes (PMNs)
Daphne Metellus
Department of Biomedical Sciences, Philadelphia College of Osteopathic Medicine

Design of Peptide Biomarkers for Complement System Activation
Dimitrios Morikis
Department of Bioengineering, University of California, Riverside

Definition of Endocrine FGF Structure as a Means to Super-agonism
Sebastian D. Parlee
Novo Nordisk Research Center Indianapolis

cGMP Peptide Production from mg to kg with Automation and Microwave-Assisted Heating
Keith A. Porter
CEM Corporation

Fluorogenic Amino Acids and Their Potential as Real-Time Probes for Protein Synthesis
Jonathan T. Rittichier
Department of Genetics, Harvard Medical School

Discovery of Novel Albumin Binding Peptides Using Rational Design and Phage Display
Buyung Santoso
Ferring Research Institute, Inc.

Using N-linked Glycosylation to Stabilize Bivalirudin
Marcus Van Engen
Department of Chemistry, Dordt College

Novel MC2R Antagonists Decrease Cortisol in Primary Human Adrenal Cortical Cells and Corticosterone in an in vivo Model of Hypercortisolism
Anastasia Velentza
Ferring Research Institute, Inc.

Establishing a Cell-Free Vibrio natriegens Expression
Daniel J. Wiegand
Department of Genetics, Harvard Medical School

An Efficient Method for the Expression and Purification of Aβ(M1–42) and N-terminal Cysteine
Stan Yoo
Department of Chemistry, University of California, Irvine

The Expression and Characterization of Disulfide-Bond Stabilized Aβ Oligomers
Sheng Zhang
Department of Chemistry, University of California, Irvine

Exploration of Mechanism of Action of Luminate®, a Therapeutic Peptide for Blinding Retinal Disease
Dan Zhoul
Division of Chemistry and Chemical Engineering, California Institute of Technology

12th Annual Peptide Therapeutics Symposium, October 2017

Cellular Manipulation through Cell Penetrating Peptide-Loaded Exosome Transfer
Jason K. Allen and Jean-Philippe Pellois
Department of Biochemistry and Biophysics, Texas A&M University

A Novel One-Pot Synthesis Strategy for Bicyclic Peptide Assembly
Angell Yvonne, Y. Wang
Department of Peptide Chemistry, ChemPartner SF

ORBIT Peptide Display—High throughput Selection of Peptides with Biological Function
Alex Batchelor, Graham Ogg
Orbit Discovery Ltd

Efficient Cell Aelivery and Lipid-specific Endosomal Escape by Aupercharged Peptides
Dakota Brock, Lauren Kustigian, Menqgiu Jian, Junjie Zhang, Hays Rye, Jean-Philippe Pellois
Texas A&M University

Effect of a Fusion Peptide by Covalent Conjugation of a Mitochondrial Cell-penetrating Peptide and a Glutathione Analog Peptide
Carmine Pasquale Cerrato, and Ülo Langel
Department of Neurochemistry, the Arrhenius Laboratories for Natural Sciences, Stockholm University

MOE Coupled with AutoDock Vina Molecular Docking and Virtual Screening Empowered Discovery of Tetrapeptides Inhibitors of Y-49 β-Lactamase
Cristina Clement, Janet Gonzalez, Manfred Philipp
Natural Sciences, LaGuardia Community College

Genetically Encoded Discovery of Chemically-Modified Peptides
Ratmir Derda
Department of Chemistry, Alberta Glycomics Centre, University of Alberta

Scaffold-based Citrullinated Peptides for Inhibition of Autoantibodies in Rheumatoid Arthritis
Camilla Eriksson, Sunithi Gunasekera, Cátia Fernandes-Cerqueira, Per-Johan Jakobsson and Ulf Göransson
Uppsala University, Department of Medicinal Chemistry, Division of Pharmacognosy, Biomedical Centre, Uppsala University

Towards Mild and Selective Incorporation of Freidinger Lactams into Expressed Peptides
Dillon Flood and Philip E. Dawson
The Scripps Research Institute

GUB06-046, a Novel Secretin/GLP-1 Co-Agonist, Decreases Food Intake, Improves Glycemic Control and Preserves Beta Cell Mass in db/db Mice
Keld Fosgerau, Søren B. van Witteloostuijn, Louise S. Dalbøge, Gitte Hansen, Knud J. Jensen, Niels Vrang,
Jacob Jelsing and Søren L. Pedersen
Department of Chemistry, University of Copenhagen

Machine Learning Techniques for Peptide Optimization from Sequence Information
Mark R. Hansen, Evgenia Razumovskaya, Jason Hodges, Hugo O Villar
Altoris, Inc. San Diego, CA; UC San Diego

Fast Synthesis of 84-mer Human Parathyroid Hormone for the Study of Osteoporosis and Hypoparathyroidism
Katya Karankevich, Daniel Martinez, Cyf Ramos-Colón and James P. Cain
Gyros Protein Technologies

A Novel Tri-Peptide Elicits Cardioprotective Effects in Myocardial Ischemia/Reperfusion Injury by an Opioid Receptor Mechanism
Hanna Kim, Anahi McIntyre, John Woodley, Alexandra Lopez, Tejaswi Dittakavi, Matt Finnegan, Kevin Amuquandoh, Maxwell Ambrosino, Kiana Walker, Harsh Patel, Qian Chen, Robert Barsotti, Lindon H. Young
Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine

Designing Cell-material Interactions by Controlling the Chemistry of the Surface of Degradable Porous Scaffolds
Tove Kivijärvi, Daniela Pappalardo, Anna Finne-Wistrand
Department of Fibre and Polymer Technology, KTH Royal Institute of Technology; Department of Science and Technology, University of Sannio

Modulation of Quorum Sensing in Streptococcus pneumoniae; An Alternative Approach to Antimicrobial Therapy
Bimal Koirala, Naiya R. Phillips, Sally R. Hamry, Yftah Tal-Gan
Department of Chemistry, University of Nevada

Characterizing the Impact of the Highly Endosomolytic Cell-Penetrating Peptide, dfTAT, on
Human Cells
Helena M. Kondow and Jean-Philippe Pellois
Department of Biochemistry and Biophysics, Texas A&M University

Investigation of Novel Cyclic Peptides for Preferential Binding to Melanocortin 4 Receptors
Maj Krumberger, C.A. Page, J. L. Rios-Monterrosa, Y. Zhou, S. Mowlazadeh Haghighi, M. Cai, V.J. Hruby
University of Arizona

Mapping Membrane Activity in Undiscovered Peptide Sequence Space Using Machine Learning
Ernest Y. Lee, Benjamin M. Fulan, Gerard. C. L. Wong, Andrew L. Ferguson
Department of Bioengineering, University of California, Los Angeles; Department of Mathematics; Materials
Science and Engineering; and Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign

On the Effects of Acylation of Cell-penetrating Peptides in Nucleic Acid Delivery In Vitro and In Vivo
Tõnis Lehto, Kadi-Liis Veiman, Helerin Margus, Kaido Kurrikoff, Margus Pooga, Mattias Hällbrink, Ülo Langel
Department of Neurochemistry, The Svante Arrhenius Laboratories for Natural Sciences, Stockholm University; Institute of Molecular and Cell Biology, University of Tartu; Institute of Technology, University of Tartu

Effective Prediction of Long-term Stability and Aggregation Propensity of Proteins via Differential Scanning Calorimetry (DSC)
Yingkai Liang, Grace Okoh, Erika Walsh, Andrew Leithead, Nicole Buist
Discovery Pharmaceutical Sciences, Merck & Co., Inc.; Oral Formulation Science & Technology, Formulation Sciences, Merck & Co., Inc.

Evaluation of Apelin-13 Analogues as Antidiabetic Therapeutics
Charlotte S. Madsena, Esben M. Becha, Rikke V. Grønlunda, Gitte Hansena, Søren L. Pedersena, Keld Fosgeraua
Gubra ApS

Myristoylated Protein Kinase C Epsilon Peptide Inhibitor Reduces Infarct Size and Improves Cardiac Function Following Myocardial Ischemia/Reperfusion (I/R)
Anahi McIntyre, Christine Adekayode, Hanna Kim, John Woodley, Tejaswi Dittakavi, Matt Finnegan, Joseph Heron, Ifeanyi James, Israel Benjamin, Stephanie Liu, Kiana Walker, Qian Chen, Robert Barsotti, Lindon H. Young
Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine

CPP and Small Molecule Synergy Enhances Endosomal Escape and Cytosolic Delivery in Live Cells
Kristina Najjar, Alfredo Erazo-Oliveras, Rudolph L. Juliano, and Jean-Philippe Pellois
Department of Biochemistry and Biophysics, Texas A&M University; Department of Nutrition and Food Science, Texas A&M University; UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill; and Department of Chemistry, Texas A&M University

Optimizing Peptide Manufacturing on the Small Scale and its Application in the Rapid Development of New Personalized Medicines
Porter, Keith, Jonathan Collins, S. Sub Singh, Michael Karney
CEM Corporation

Novel Therapeutic Peptides Targeting Matricellular Signaling in Currently Untreatable Fibrotic Disease and Cancer
Bruce L. Riser, Dorina Belotti, and Giulia Taraboletti
BLR Bio LLC; The Department of Physiology and Biophysics, and Department of Medicine, Rosalind Franklin University of Medicine and Science; and Mario Negri Institute of Pharmaceutical Research

Improved Florescent Amino Acids For In Situ Labeling of Bacterial Cell Walls
Jonathan Rittichier, Erkin Kuru1, Yen-Pang Hsu, Yves V. Brun, Michael S. VanNieuwenhze, and George M. Church
Harvard Medical School; Indiana University

Development of a New Method on Npys-based Disulfide Bond Formation for the Preparation of Bioactive Cyclic Disulfide Peptides
Akihiro Taguchi, Kiyotaka Kobayashi, Akira Kotani, Kyohei Muguruma, Misaki Kobayashi, Kentarou Fukumoto, Kentaro Takayama, Atsuhiko Taniguchi, Hideki Hakamata, Yoshio Hayashi1
Department of Medicinal Chemistry and Department of Analytical Chemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences; Kokusan Chemical Co., Ltd.

Discovery of Selective Hexapeptide Agonists to Human NMUR1 and NMUR2
Kentaro Takayama, Kenji Mori, Akiko Tanaka, Akihiro Taguchi, Atsuhiko Taniguchi, Toshiyasu Sakane, Akira Yamamoto, Naoto Minamino, Mikiya Miyazato, Kenji Kangawa, and Yoshio Hayashi
Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences; Department of Biochemistry, National Cerebral and Cardiovascular Center Research Institute; Department of Biopharmaceutics, Kyoto Pharmaceutical University; Laboratory of Pharmaceutical Technology, Kobe Pharmaceutical University; and Omics Research Center, National Cerebral and Cardiovascular Center

Highly Efficient Synthesis of Therapeutic Macrocyles by Ligases
James P. Tam and Xinya Hemu
Nanyang Technological University, School of Biological Sciences

Computational Design and Experimental Characterization of Peptides Intended for pH-Dependent Membrane Insertion and Pore Formation
David Tellers
Merck and Co., Inc.

Plasma Protein Binding Analysis of Peptides with a Novel Single-compartment Mass Spectrometry Assay
Jan Ungewiss, Hinnerk Boriss
3B Pharmaceuticals GmbH; Sovicell GmbH

Targeting Quorum Sensing in Streptococcus Pneumoniae: An Alternative Antibacterial Approach
Yifang Yang, Bimal Koirala, Lucia A. Sanchez, Gabriel Cornilescu, and Yftah Tal-Gan
Department of Chemistry, University of Nevada, Reno; National Magnetic Resonance Facility at Madison,
University of Wisconsin-Madison

N-linked Glycosylation Prevents Deamidation of Glycopeptide and Glycoprotein
Hailiang Zhu, Ding Liu, Vy P Tran, Zhigang Wu, Kuan Jiang, He Zhu, Xu Li, Xifang Liu, Jingyao Qu, Bingzhong Xue, Hang Shi, and Peng George Wang
Department of Chemistry, Georgia State University; Department of Biology, Georgia State University; Department of Chemistry, Dordt College

Structure-Based Design, Synthesis and Evaluation of Constrained Seven Membered Ring-Containing Tetrapeptides Lead to Selective Human Melanocortin 1 Receptor
S. Mowlazadeh Haghighi, Y. Zhou, J.R. Sawyer, A.C. Ho, J. Rios- Monterrosa, V.J. Hruby, M. Cai
Department of Chemistry and Biochemistry, University of Arizona

11th Annual Peptide Therapeutics Symposium, October 2016

Asprosin, a Fasting-Induced Glucogenic and Orexigenic Protein Hormone
Atul Chopra, M.D., Ph.D.,  Caroline Wiess Law Scholar, Assistant Professor, Department of Molecular and Cellular Biology, Department of Molecular and Human Genetics, Baylor College of Medicine

Tailoring Peptides for less Frequent Dosing and Non-invasive Delivery
Jesper Lau, Ph.D., Vice President, Diabetes Protein and Peptide Chemistry, Diabetes Research Unit, Novo Nordisk A/S

Non- Peptide GLP-1 Receptor Agonists; From Idea to Medicine
Carmen Valcarce, Ph.D., Senior Vice President and Chief Scientific Officer, vTv Therapeutics

Structural Elucidation of Ligand Binding Sites in Class B GPCRs and their Application in Drug Discovery
Ali Jazayeri, Ph.D., Chief Technology Officer, Heptares Therapeutics

Selective Inhibition of Cytokines with Peptide Therapeutics: A Unique Alternative to Conventional MAB and JAK Inhibitor Approaches for Cytokine Modulation
Nazli Azimi, Ph.D., Founder, President and CEO, Bioniz Therapeutics, Inc.

Peptide-based Strategies to Treat Inflammatory and Autoimmune Diseases: From the Peptide P140 to Lupuzor™
Sylviane Muller, Ph.D., Professor and CNRS Director, Molecular and Cellular Biology Institute, University of Strasbourg

Innovation by Evolution: Expanding the Enzyme Universe
Frances H. Arnold, Ph.D., Dickinson Professor of Chemical Engineering Bioengineering and Biochemistry, Division of Chemistry and Chemical Engineering, California Institute of Technology

Novel Synthetic Strategies for Insulin and Related Peptides
Fa Liu, Ph.D.,  Director of Chemistry, Novo Nordisk Research Center-Indianapolis

AB103: Host-Oriented Therapeutics to Control Life Threatening Infections
Anat Shirvan, Ph.D., Executive Vice President, Research & Development, Atox Bio, Ltd.

Engineering Potent and Selective Inhibitors of Nav1.7 Sodium Channel
Les Miranda, Ph.D., Director Research, Hybrid Modality Engineering, Structural Biology, & Molecular Modeling, Therapeutic Discovery, Amgen Inc.

Taregting Novel Polysaccharide-binding Proteins to Block Tissue Fibrosis
Eva Turley, Ph.D., Chief Scientist, Novare Pharmaceuticals

TLQP-21 and C3aR1, a Novel Ligand/Receptor Target for Lipolysis and Obesity
Alessandro Bartolomucci, Ph.D., Associate Professor of Physiology, Department of Integrative Biology and Physiology, University of Minnesota

Discovery and Clinical Development of Elamipretide
Hazel H. Szeto, M.D., Ph.D., Adjunct Professor, Weill Cornell Medicine

Unlocking the Mysteries of Amyloid Diseases with Macrocyclic β-Sheet Peptides
James S. Nowick, Ph.D., Professor of Chemistry and Department Chair, University of California, Irvine

Endocrine FGFs and Structure-Activity-Relationship
Alexei Kharitonenkov, Ph.D., Professor, Department of Chemistry, Indiana University

New Therapeutics from the Human Microbiome: Discovery of Novel Proteins and Peptides for the Treatment of Gastrointestinal Barrier Related Disorders
Karim Dabbagh, Ph.D., Chief Scientific Officer, Second Genome, Inc.

Chemo-enzymatic Peptide Synthesis (CEPS): A Generally Applicable, Traceless Ligation Technology for the Synthesis of Peptide-to-peptide and Peptide-to-protein Conjugates
Timo Nuijens, Ph.D., Lead Scientist, EnzyPep

InGell® – Injectable Drug Depots for Short and Mid-term Release of Soluble and Non-soluble API’s
Mike G.W. de Leeuw, MSc, BBA, Founder and Chief Business Officer, InGell Labs BV

Errata located at the end of the Symposium PDF

10th Annual Peptide Therapeutics Symposium, October 2015

Building Better Medicines: Translational Research in the 21st Century
Roger M. Perlmutter, M.D., Ph.D.  Executive Vice President and President, Merck Research Laboratories

An Integrated View of the Adipocyte: From Feast to Famine
Philipp E. Scherer, Ph.D.  Professor, Department of Internal Medicine, Gifford O. Touchstone Jr. and
Randolph G. Touchstone Distinguished Chair in Diabetes Research; Director,
Touchstone Diabetes Center, The University of Texas Southwestern Medical Center

Oral Peptide Delivery: Deciphering the Reality from the Hype
David J. Brayden, Ph.D.  Professor of Advanced Drug Delivery, University College Dublin

Oral Inhalation – A Simple Approach to Biologics Delivery
John Freeman, M.S.  Principal Scientist, MannKind Corporation

ITCA 650 (Exenatide Delivered Continuously via a Matchstick-Size Subcutaneous
Osmotic Mini-Pump) an Investigational Therapy for Type-II Diabetes
Scott Peterson, Ph.D.  Executive Director, Corporate Development, Intarcia Therapeutics, Inc.

MICROCOR® Transdermal System: Technology Overview and Clinical Status
Bobby Singh, Ph.D.  Chief Technology Officer, Corium International, Inc.

Activity-based Proteomics – Applications for Enzyme and Inhibitor Discovery
Benjamin F. Cravatt, Ph.D.  Professor and Chair, Department of Chemical Physiology, The Scripps Research

Molecular Targets for the Effects of Bariatric Surgery on Obesity and Diabetes
Randy J. Seeley, Ph.D.  H.K. Ransom Professor of Surgery, University of Michigan

Harnessing Chemistry and Glycoproteins to Discover Novel Targets for Cancer
Therapy and Neurodegenerative Diseases
Linda C. Hsieh-Wilson, Ph.D.  Professor of Chemistry, Division of Chemistry and Chemical Engineering, California
Institute of Technology

Engineered Cystine Knot Peptides: A New Class of Tumor Targeting Agents
Jennifer R. Cochran, Ph.D.  Associate Professor, Department of Bioengineering, and (by courtesy) Chemical
Engineering, Stanford University

Phage Selection of Bicyclic Peptides for Application as Therapeutics
Christian Heinis, Ph.D.  Assistant Professor, École Polytechnique Fédérale de Lausanne (EPFL)

Kisspeptin and its Short-length Agonist Analogues: Discovery and Development
Taiji Asami, Ph.D.  Associate Director, Takeda Pharmaceutical Company Ltd.

Phage-display Derived Peptidic Inhibitors of PCSK9 for LDL Cholesterol Lowering
Daniel Kirchhofer, Ph.D.  Principal Scientist, Department of Early Discovery Biochemistry, Genentech, Inc.

Improved Chemical and Physical Stability in Liquid Formulations – How to Design
Stable Glucagon Analogues
Lise Giehm, Ph.D.  Senior Scientist, Department of Pharmaceutical Development, Zealand Pharma A/S

Selepressin, a Selective hV1a Agonist for the Treatment of Hypotension in Septic Shock
Claudio D. Schteingart, Ph.D.  Director, Peptide Therapeutics Foundation
Vice President, Science & Technology – Research, Ferring Research Institute Inc.

Addressing the Challenges with the Discovery and Development of Peptide
Paul L. Feldman, Ph.D.  Head of Discovery and Translational Medicine, Intarcia Therapeutics Inc.
Former CEO & Co-founder, Phoundry Pharmaceuticals

NA-1: From Bench to Bedside – A Novel Peptide Therapeutic for the Treatment of
Acute Stroke
Dave Garman, Ph.D.  Technology Officer, NoNO Inc.

Relamorelin, a Ghrelin Agonist for the Treatment of Diverse Functional
Gastrointestinal Disorders
Lex H.T. Van der Ploeg, Ph.D.  Chief Scientific Officer, Rhythm Pharmaceuticals

9th Annual Peptide Therapeutics Symposium, October 2014

Multiselective Peptides for the Treatment of Metabolic Diseases by Cristina Rondinone, Ph.D., Vice President, Research and Development, Head Cardiovascular/Metabolic Diseases iMED, Medimunne

Peptide Agonists of Incretin Receptors Are High Priority Candidates in the Search for the First Effective Treatments of Alzheimer’s Disease by Konrad Talbot, Ph.D., Associate Professor, Department of Neurosurgery, Cedars-Sinai Medical Center

Continuous Glucose Monitoring: Technology that will Bridge the Gap until there is a Cure for Type 1 Diabetes by Steven Edelman, M.D., Professor of Medicine, University of California San Diego, Veterans Affairs Medical Center , Founder and Director, Taking Control of Your Diabetes 501(c)3

Peptide Therapeutics: A New Golden Age by Richard A. Houghten, Ph.D., Founder, President & CEO, Torrey Pines Institute for Molecular Studies

New Physiology and Pharmacology of the Melanocortin-4 Receptor by Roger D. Cone, Ph.D.,Professor and Chair, Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center

Chemoenzymatic Approaches in Amide-to-amide Peptide Ligation by James P. Tam, Ph.D. , Professor, Herbalomics and Drug Discovery, School of Biological Sciences, Nanyang Technological University

Hepcidin and Minihepcidins: From Mechanistic Studies to Therapeutic Peptides by Tomas Ganz, Ph.D., M.D., Professor of Medicine and Pathology, University of California, Los Angeles

Discovery of Functional Ligands and Materials from Genetically-encoded Libraries of Chemically-modified Peptides by Ratmir Derda, Ph.D.,Assistant Professor, Department of Chemistry and Alberta Glycomics Centre, University of Alberta

Using the Endosome Escape Trap to Discover Phylomer Peptides which more Efficiently Deliver Cargoes to the Cytoplasm by Paul Watt, D.Phil., Chief Scientific Officer, Phylogica Ltd

Danegaptide – Potential First and Best in Class Peptide Medicine for Prevention of Myocardial Reperfusion Injury by Rie Schultz Hansen, MSc, Ph.D. , Principal Scientist, Zealand Pharma A/S

Arylomycin Antibiotics by Floyd E. Romesberg, Ph.D., Assistant Professor, Department of Chemistry The Scripps Research Institute

Novel Peptide Therapeutics Targeting Key Intracellular Signaling Pathways of Cancer Stem Cells by Jörg Vollmer, Ph.D., Managing Director and Chief Executive Officer, Nexigen GmbH

Peptide Antagonists of the Inflammatory Response Enhanced by the Antimicrobial Peptide LL-37 by Cheng Kao, Ph.D. , Director of Biotechnology and Professor, Department of Molecular & Cellular Biology, Indiana University

Integrated Triple Gut Hormone Action Broadens the Therapeutic Potential of Endocrine Biologics for Metabolic Diseases by Brian Finan, Ph.D. Division Head, Helmholtz Zentrum Munich

8th Annual Peptide Therapeutics Symposium, October 2013

The Structural and Energetic Basis of Carbohydrate–Polypeptide Stabilizing Interactions Within Enhanced Aromatic Sequons in Protein Native States by Jeffery W. Kelly, The Scripps Research Institute

Developing IMS-MS Techniques as a means of Following Structural Transitions of Biopolymers in Solution by David E. Clemmer, Indiana University

Half-Life Extension Through HESylation® by Martin Meyer, Fresenius Kabi Deutschland GmbH

Long-acting Release of Drug Peptides by in situ Gelling FluidCrystal® Injection Depot by Fredrik Tiberg, Camurus AB

The Transdermal Delivery of Peptides and other Biotherapeutics by Frank Tagliaferri, 4P Therapeutics

Structural Insights into HIV, Influenza & HCV Antigen Design by Ian A. Wilson, The Scripps Research Institute

How Insulin Binds: Structure of a Micro-receptor Complex and Implications for Analog Design by Michael A. Weiss, Case Western Reserve University

Mimicry of Hormone Recognition Surfaces with Peptidic Foldamers by Samuel H. Gellman, University of Wisconsin, Madison

ShK-186, a Peptide Inhibitor of Kv1.3 Potassium Channels as Therapy for Autoimmune Diseases and Metabolic Syndrome by K. George Chandy, University of California, Irvine

The Tale of Two Peptides Rescuing a Company in Distress by Roger J. Garceau, NPS Pharmaceuticals, Inc.

Towards Optimized Utility of Proteasome Inhibitors with Peptide Epoxyketones by Christopher J. Kirk, Onyx Pharmaceuticals, Inc.

Direct Selection of Highly Potent Cyclic Peptidomimetics from In Vitro Display Libraries by Douglas A. Treco, Ra Pharmaceuticals, Inc.

Development of Serelaxin for Acute Heart Failure by Dennis Stewart, Corthera Inc., Novartis Pharmaceuticals Corp.

SOM230: A New Therapeutic Modality for Cushing’s Disease by Ian Lewis, Novartis Institutes of Biomedical Research

PeptiDream’s PD Platform: Innovative Peptide Discovery Platform by Patrick C. Reid, Peptidream Inc.

Design of Peptide Therapeutics Exhibiting Dual Pharmacology and Extended Duration of Action by Soumitra Ghosh, Amylin Pharmaceuticals LLC

The Development of BA058, a Novel Peptide, for the Treatment of Osteoporosis by Gary Hattersley, Radius Health, Inc.

99mTc-Galacto-RGD2: A novel 99mTc-Labeled Cyclic RGD, Peptide Dimer Useful for Tumor Imaging by  Michael Pennington, Peptides International, Inc.

View Program
View Digital Copy

7th Annual Peptide Therapeutics Symposium, October 2012

Chemoselective Strategies for the Synthesis of Complex Assemblies of Peptide by
Philip Dawson, Ph.D., Associate Professor of Cell Biology & Chemistry, The Scripps Research Institute

Cell-penetrating Peptides with Intrinsic Biological Activity by Francesca Milletti, Ph.D., Head, Cheminformatics & Statistics, Roche Pharmaceuticals

Peptide Macrocyclization Enabled by Amphoteric Molecules by Andrei K. Yudin, Ph.D., Professor, Davenport Research Laboratories, Chemistry Department,
University of Toronto

The State of Pharmaceutical Innovation by Bernard Munos, MBA, Founder, InnoThink Center for Research in Biomedical Innovation

Design of Therapeutics that Act on Membranes and Membrane Proteins by Bill DeGrado, Ph.D., Professor, Department of Pharmaceutical Chemistry; Investigator, Cardiovascular
Research Institute, University of California, San Francisco

Gut-peptide Based Poly-pharmacy for the Treatment of Obesity & Diabetes by Matthias Tschöp, M.D., Alexander-von-Humboldt Professor; Director, Institute for Diabetes and
Obesity, German Center for Diabetes Research, Helmholtz Center Munich

Omontys: Beating the Odds in the Journey of a Drug from Bench to Bedside
Anne-Marie Duliege, M.D., M.S., Chief Medical Officer, Affymax, Inc.

Identification and Characterization of KAI-4169, A Novel Peptide for the Treatment
of Secondary Hyperparathyroidism by Gregory M. Bell, M.D., Senior Vice President, Development, KAI Pharmaceuticals

Stapled Peptide Drugs: Translation to the Clinic by Tomi K. Sawyer, Ph.D., Chief Scientific Officer and Senior-Vice President, Drug Discovery and Innovative
Technologies, Aileron Therapeutics

LY2605541, a Novel Long-acting Basal Insulin by Mel Prince, M.D. Senior Medical Director, Lilly Diabetes, Eli Lilly and Company

NMDA Receptor Modulating Peptides with Therapeutic Potential: From Monoclonal Antibodies to the Creation and Development of GLYX-13 by Joseph R. Moskal, Ph.D., Professor and Director, The Falk Center for Molecular Therapeutics, McCormick School of Engineering and Applied Sciences, Dept. of Biomedical Engineering, Northwestern University

XEP-018: A New Myorelaxant Peptide Lead Compound from the Venom of the
Cone Snail Conus consors by Reto Stöcklin, Ph.D., President & CEO, Research & Development, Atheris Laboratories

XTENylation Offers a Biodegradable Alternative to PEGylation by Volker Schellenberger, Ph.D., Chief Scientific Officer, Amunix, Inc.

Tunable Half-life Extension of Therapeutics by Controlled Chemical Release from
Macromolecular Conjugates by Daniel V. Santi, M.D., Ph.D., President, ProLynx LLC; Professor, University of California, San Francisco

Development of Modified Human Serum Albumins for Peptide and Protein Half-life Extension: Towards Monthly Dosing by Mark Perkins, Ph.D., Customer Solutions Manager, Novozymes Biopharma UK Ltd.

Clinical Development of a Novel PTH Analog for the Treatment of Osteoporosis with an
Optimized Oral Tablet Formulation by Nozer Mehta, Ph.D., Vice President, Research and Development, Unigene Laboratories, Inc.

View Digital Copy

6th Annual Peptide Therapeutics Symposium, October 2011

Discussion about factors driving R&D funding today
Hans-Joachim Böhm, Ph.D.Director, Peptide Therapeutics Foundation, Global Head of Chemistry, Roche; Center Manager, Roche Pharma Research & Early Development Site Basel
Stan Crooke, M.D., Ph.D., Chairman of the Board and CEO, Isis Pharmaceutical, Inc.
Rodney Lappe, Ph.D., Director, Peptide Therapeutics Foundation, Group Sr. Vice President, Pfizer Worldwide Research & Development; Chief Scientific Officer, CovX Research

Development of a Long-acting C-peptide (ErsattaÔ) by James Callaway, Ph.D. President and CEO, Cebix Incorporated
Michel Pettigrew, MBA, President of the Executive Board & Chief Operation Officer, Ferring Pharmaceuticals

Long Acting Y2R Peptide Mimetic as a New Generation Therapeutic Agent for the Management of T2D by Waleed Danho, Ph.D., Distinguished Research Leader, Hoffmann- La Roche Inc.

Somatostatin-Dopamine Chimeric Molecule for Potential Treatment of Pituitary Adenomas and Neuroendocrine Tumors by Jesse Z. Dong, Ph.D., Director, Peptide Therapeutics Foundation, Vice President, Compound Discovery, Ipsen
An Expanding Genetic Code by Peter Schultz, Ph.D., Scripps Family Chair Professor, Department of Chemistry, The Scripps Research Institute

Targeting Protein Therapeutics Across the Blood-Brain Barrier with Molecular Trojan Horses by William M. Pardridge, Ph.D., Distinguished Professor of Medicine, University of California, Los Angeles

Neuropeptidomics: From the Discovery of New Neuropeptides to the Elucidation of their Functions by Jonathan Sweedler, Ph.D., Professor of Chemistry, James R. Eiszner Family Chair, University of Illinois, Urbana-Champaign

Comparative Peptidomic Analysis for Functional Discovery of Neuropeptides by Lingjun Li, Ph.D., Professor, School of Pharmacy and Department of Chemistry, University of Wisconsin

High Resolution Mass Spectrometry-Based Profiling of Secreted Peptides for Drug Discovery by Steven Taylor, Ph.D.
Director of Chemistry, Amylin Pharmaceuticals; Research Associate, Scripps Institution of Oceanography

EPiC Technology: Using Peptide to Physiologically Cross the BBB by Jean Paul Castaigne, M.D., MBA, President and CEO, AngioChem

Endogenous Peptides to Safely Enhance the Delivery of (peptide) Drugs to the Brain by Willem van Werperen, MSc, MBA, CEO, to-BBB

Enhancing CNS Uptake of Biologics through Molecular Engineering by Ryan Watts, Ph.D., Associate Director, Head of Neurodegeneration Labs, Department of Neuroscience, Genentech, Inc.

NPY2R Selective Peptide Agonists for the Treatment of Obesity: Balancing Efficacy, Time Action and Cardiovascular Profile by Jordi Alsina, Ph.D., Senior Research Scientist, Eli Lilly & Company

Development Of CR845, a Novel, Peripherally-Acting Peptidic Kappa Opioid Agonist, for the Treatment of Postoperative Pain by Derek Chalmers, Ph.D., D.Sc., President & CEO, Cara Therapeutics, Inc.

ZYPH0907: A Novel Orally Active PTH1R Agonist for Treatment of Osteoporosis by Mukul Jain, Ph.D.,Senior Vice President, ZydusResearch Center

5th Annual Peptide Therapeutics Symposium, October 2010

Venture Capital panel discussion: Attractive Financing Structures for Emerging Biotechnology Companies.
John Diekman, Ph.D., Founder & Managing Partner, 5AM Ventures
Shehan Dissanayake, PhD, CEO, Tavistock Life Sciences
Malcolm Finlayson, Ph.D., Venture Partner, Hamilton Bioventures
Pratik Shah, Ph.D., Venture Partner, Thomas, McNerney & Partners

Chemical Synthesis in the Development of Protein Therapeutics by Stephen B.H. Kent, Ph.D., Professor, Department of Chemistry, University of Chicago

Chemically Programmed Immunity: Making Peptides Drugs and More by Carlos Barbas III, Ph.D., Janet and Keith Kellogg II Chair in Molecular Biology Professor, Department of Molecular Biology, The Scripps Research Institute

Tumor-penetrating Peptides in Targeted Tumor Treatment by Erkki Ruoslahti, M.D., Ph.D., Distinguished Professor, Sanford-Burnham Medical Research Institute

Glioblastoma: Cancer Stem Cells and Reprogramming by Inder Verma, Ph.D., Professor, Irwin and Joan Jacobs Chair in Exemplary Life Science, Laboratory of Genetics and American Cancer Society Professor of Molecular Biology, Salk Institute for Biological Studies

From Combinatorial Chemistry to Nanoparticles to Cancer Imaging and Therapy by Kit Lam, M.D., Professor and Chief, Hematology and Oncology, University of California Davis Cancer Center

Protein Engineering: A Key Innovation Path for Novel Biopharmaceuticals by Thomas Bumol, Ph.D., President, Applied Molecular Evolution & Vice President Biotechnology, Lilly Research Laboratory

Early Clinical Development of Novel Biologics by Richard Jones, M.D., Chief Medical Officer, Syntaxin

Ligand-receptor Fusions for the Generation of Long-acting Biopharmaceuticals by Richard Ross, M.D., Chief Scientific Officer and Director, Asterion

Antibody Drug Conjugates: Current and Future Developments by Hans-Peter Gerber, Ph.D., Senior Director Pfizer

Enhancing the Activities of Monoclonal Antibodies for Cancer Therapy by Peter Senter, Ph.D., Vice President Chemistry, Seattle Genetics

New Horizons in Protein Medicinal Chemistry Enabled with an Expanded Genetic Code by Ho Sung Cho, Ph.D., Chief Technical Officer, Ambrx Inc.


4th Annual Peptide Therapeutics Symposium, November 2009

Update on development trends for peptide therapeutics by Janice M. Reichert, Ph.D., Senior Research Fellow, Tufts Center for the Study of Drug Development.

New Targets and Targeting Mechanisms for Contrast Agents and Therapeutics by Roger Tsien, Ph.D., HHMI Investigator& 2008 Nobel Laureate Chemistry, Professor Pharmacology, Chemistry and Biochemistry, UCSD.

NMR structural studies of drug receptors in membranes by Stanley Opella, Ph.D., Professor Chemistry and Biochemistry & Director Nuclear Magnetic Resonance Resource Lab, UCSD.

Peptide transduction domain mediated delivery of macromolecules; Tackling the siRNA delivery problem by Steven F. Dowdy, Ph.D., HHMI Investigator & Professor Cellular and Molecular Medicine, School of Medicine, UCSD

Peptide inhibitors of protein-protein interactions; From rational design to the clinic by Daria Mochly-Rosen, Ph.D., Professor, Chemical and Systems Biology & Senior Associate Dean for Research, School of Medicine, Stanford University.

Stapled helical peptides: A new drug modality by Noriyuki Kawahata Ph.D., Senior Principal Scientist Chemistry, Aileron Therapeutics.

Clinically validated inhibitors of intracellular protein interactions by Stephen D. Harrison, Ph.D., Senior Vice President, Research, Kai Pharmaceuticals.

Pepducins – Novel mediators of GPCR signaling by Stephen Hunt, Ph.D., Senior Vice President, Discovery Research, Ascent Therapeutics.

Linaclotide: A potential therapy for IBS-C by Mark G. Currie, Ph.D., Senior Vice President, R&D & CSO, Ironwood Pharmaceuticals Inc.

Non-Invasive systemic delivery of peptides with high bioavailability by Edward T. Maggio, Ph.D., CEO & Director, Aegis Therapeutics.


3rd Annual Peptide Therapeutics Symposium, October 2008

CovX-Body Biotherapeutics: From Concept to Applications by Joel Desharnais, Ph.D. Senior Scientist, CovX

Sustained Release of Peptides Using Microencapsulation and the Development of Long Acting Exenatide by Paul Herbert, Vice President Process Development Alkermes , Inc.
V1a Agonists in Vasodilatory Shock: From Bedside to Bench, and Back by Donald W. Landry, M.D., Ph.D., Chair, Department of Medicine, Columbia University
LAPSCOVERY Technology and Its Application to Long Acting Peptide/Protien Drugs by Gwan Sun Lee, Ph.D., Managing Research Director, Hanmi Research Center, Hanmi Pharm. Co., Ltd

Engineering Kunitz Domains Using Phage Display by Andrew E. Nixon, Ph.D., Vice President, Lead Discovery and Biochemistry, Dyax Corporation

Preformed Conjugate-Drug Affinity Complex (PC-DAC™) Technology by Martin Robitaille, Ph.D., Director, Peptide Chemistry, Conjuchem Biotechnologies, Inc.

Trends in the Clinical Development and Approval of Synthetic Peptides by Janice Reichert, Ph.D., Senior Research Fellow, Tufts Center for the Study of Drug Development


2nd Annual Peptide Therapeutics Symposium, November 2007

Building, Understanding and Leveraging a Peptide Library by Michael Hanley, Ph.D., Vice President Discovery Research, Amylin Pharmaceuticals

Application of Chemical Biotechnology to the Optimization of Protein Therapeutics by Richard Dimarchi, Ph.D., Professor, Department of Medicinal Chemistry, Indiana University

Degarelix: a novel GnRH antagonist for the treatment of prostate cancer by Per Cantor, M.D., Ph.D., Senior Vice President Clinical and Non-Clinical Development, Ferring Pharmaceuticals

KL-4 Surfactant – Form to Function by Charles Cochrane, M.D., Professor, Department of Immunology, The Scripps Research Institute

The Commercialization of Fuzeon® API by Brad DeHoff, Ph.D., Technical Manager, Roche Colorado Corp.

The Beta Cell Hormone Amylin: Discovery and Clinical Application by Andrew Young, M.D., Ph.D., Vice President , Senior Research Fellow, Amylin Pharmaceuticals

“Ynot Y2 and Y4 Peptide Agonists for Treatment of Diabetes and Obesity?” by Thue Schwartz, M.D., CSO, 7TM Pharma, University of Copenhagen

Oxyntomodulin or Products of the PYY Preproglucagon gene by Steve Bloom, M.D., Professor of Medicine, Imperial College, London


1st Annual Peptide Therapeutics Symposium, November 2006

Medicinal Chemistry of Peptide Hormones by Victor Hruby, Ph.D., Regents Professor of Chemistry, University of Arizona

GnRH: a Peptide for All Seasons by Robert Millar, Ph.D., Director, MRC Human Reproductive Sciences Unit, Ardana

Desmopressin, a Selective Antidiuretic Analog of Vasopressin by Jens Peter Norgaard, Ph.D., CSO, Urology, Ferring Pharmaceuticals
Osteoporosis, Regenerating Bone and Parathyroid Hormone by Michael Rosenblatt, Ph.D., Dean, Tufts University Medical School

History of the Development of Byetta: The Vicissitudes of Drug Development in Biotechnology by Alain D. Baron, Ph.D., Sr. Vice President, Research, Amylin Pharmaceuticals

Clinical Applications of the GLP-2 Analogue Teduglutide by Derek Chalmers, Ph.D., President  & CEO, Cara Therapeutics

Current Status of Methods for Large-Scale Production of Peptides Michael Verlander, Executive Vice President, Ph.D., Polypeptide Laboratories, Inc.


Symposium 1-5

For more information regarding Symposiums 1-5, please contact us.